New faces

New faces

07.03.2013 - German Alzheimer specialist Probiodrug AG has widened its management team by two new positions. Ronald Black will take over as Chief Medical Officer, while Inge Lues has been appointed Chief Development Officer.

Before joining Probiodrug, Black held various senior research roles at Pfizer and at Wyeth Pharmaceuticals prior to its acquisition by Pfizer. Most recently he was the assistant vice president of the firm's Alz-heimer immunotherapy programme. The native of the US has been involved with two New Drug Applications and eight Investigational New Drug filings, and has authored more than 40 publications. From 2008 until joining Probiodrug, Inge Lues acted as an R&D adviser to venture capital and biotechnology companies. During this period, she helped Probiodrug identify drug candidates and advance them into clinical studies. Previously the physiologist was the Executive Vice President Global Drug Discovery and Non-clinical Development at German Merck KGaA (Darmstadt).

19.04.2013 French diabetes specialist Poxel SA (Lyon) has beefed up its business strategy expertise by appointing Khoso Baluch to its Board of Directors.

Baluch is currently Senior VP & President European Region at Belgian UCB SA. Prior to his career there, he worked with Eli Lilly for 24 years, holding international positions in General Management, Business Development, Market Access and Product Leadership. He served as a Board Member of the Juvenile Diabetes Research Foundation, Indiana Chapter, and was Chair of the nomination committee. He also served at the American Diabetes Association National Industry Advisory Board and is also a member of the World Federation of Advertisers (WFA) Executive Committee. Poxel was spun-out from Merck Serono in 2009.

22.04.2013 Molecular diagnostics specialist Curetis AG (Holz-gerlingen) is expanding into new markets with ELI-Tech BNL as a new partner in Belgium and Luxembourg, and it has also acquired a new Head of Business Development.

Helmut Hilbert, a former Associate Director of Corporate Business Development at Qiagen, will strengthen the company's global commercial operations. Hilbert has more than ten years of business and corporate development experience, and has a strong track record in licensing, mergers and acquisitions, technology transfer and innovation management.

23.04.2013 Oern Stuge has taken over from Henry Hyde Thomson as Chairman at Phagenesis plc (Manchester) to support the rollout of the company’s dysphagia therapy Phagenyx.

Stuge previously served as Senior Executive at Medtronic and Abbott Laboratories. He began his career as a practicing physician. He has an MD from the University of Oslo, as well as an MBA from IMD in Lausanne.

03.05.2013 Paris-based developer of non-viral gene therapy for ocular diseases Eyevensys SA has named Dr. Ivan Cohen-Tanugi as its new CEO.

Cohen-Tanugi brings the company more than 20 years of experience in the international pharmaceutical industry. He will prepare Eyevensys to launch clinical trials for the company's non-viral gene therapy products in two ophthalmic indications - uveitis and age-related macular degeneration - within the next 18 months. Cohen-Tanugi has considerable experience in biologics and in the pharmaceutical industry at an international level, notably in the fields of sales and marketing, global product launches, R&D team leadership and financing. The physician and MBA joins Eyevensys from Teva Pharmaceuticals, where he was Vice President and General Manager of the US Biologics and Specialty unit. Cohen-Tanugi began his career at Sanofi, then worked for many years with Roche Pharma in Basel. Prior to his activities at Teva, he was employed with Amgen International.

06.05.2013 Swedish Vitrolife AB proposed Carsten Browall as new Chairman of the Board.

He will follow Patrik Tigerschiöld, who declined reelection after 13 years on the Board and 11 years as its Chairman. Browall has been a member of the Vitrolife Board since 2012, and has many years of experience as an executive within the med-tech and healthcare sector. During his career he has worked at Unfors RaySafe, Mölnlycke Health Care, Nobel Biocare and Capio.

07.05.2013 Rentschler Biotechnologie GmbH has named a seasoned industry expert as its new Chief Business Officer (CBO). Frank Ternes comes in from Boehringer Ingelheim, where he worked for 25 years, most recently as Senior Vice President of Biopharmaceutical Contract Manufacturing.

Rentschler Biotechnologie GmbH has named a seasoned industry expert as its new Chief Business Officer (CBO).

Frank Ternes comes in from Boehringer Ingelheim, where he worked for 25 years, most recently as Senior Vice President of Biopharmaceutical Contract Manufacturing. Ternes will lead the planning, development and execution of all business development, sales & marketing and project management activities for the German CRO, which began short-time work at the end of March due to “high market volatility”.

10.05.2013 Claus Schollmeier has left Swiss Santhera AG to follow in the footsteps of Suppremol CEO Peter Buckel, who is resigning.

Schollmeier has led Santhera since its foundation in 2004, and in 2011 became head of the firm's board. Prior to that, the biologist was Managing Director of Healthcare/Biotechnology at investment bank ING BHF.

13.05.2013 Norwegian targeted radio-cancer therapy specialist Algeta ASA (Oslo) has added Hilde Furberg as Non-executive Director to its board.

The nuclear chemist has 30 years of experience in the pharmaceutical industry. Furberg is currently Senior VP Rare Disease EMEA at Genzyme (now Sanofi). Prior to Genzyme, she spent 15 years at Baxter. She is a Non-executive Director on the Board of Clavis Pharma ASA, and is also a board member at Copenhagen Capacity. Her previous board memberships include Probi AB and Pronova Biopharma ASA (until its acquisition by BASF).

14.05.2013 Dr. Michel Pairet, Boehringer Ingelheim's head of non-clinical R&D, has joined Eyevensys' board of directors.

The appointment followed an investment from the Boehringer Ingelheim Venture Fund in the French developer of electrotransfer-based non-viral gene therapy. Prior to his responsibilites for preclinical research, Pairet was in charge of Boehringer's worldwide research and its corporate investment fund.

17.05.2013 Scancell Holdings plc has named Peter Allen as its Non-Executive Director.

The therapeutic cancer vaccines developer announced it had hired the current Chairman of Clinigen, Chroma Therapeutics, ProStrakan, and Future in April.  Allen brings the firm a broad spectrum of experience ranging from fundraising to restructuring, IPOs to M&As. During his 12-year tenure at Celltech, he led acquisitions of Chiroscience, Medeva and Oxford Glycosciences.

Vorherige Seite3/8Nächste Seite


Current issue

All issues

Product of the week


Stock list

All quotes


  • HYBRIGENICS (F)0.94 EUR8.05%
  • IXICO (UK)31.50 GBP5.00%


  • ARGEN-X (B)13.70 EUR-3.52%
  • VECTURA (UK)132.10 GBP-3.17%
  • SAREUM HOLDINGS (UK)0.72 GBP-2.70%


  • MOLMED (I)0.42 EUR27.3%


  • BIONOR PHARMA (N)0.42 NOK-22.2%
  • ACTIVE BIOTECH (S)12.20 SEK-18.4%
  • E-THERAPEUTICS (UK)11.50 GBP-14.1%


  • NICOX (F)10.31 EUR439.8%
  • SAREUM HOLDINGS (UK)0.72 GBP227.3%
  • GENMAB (DK)1095.00 DKK89.8%


  • BB BIOTECH (D)44.55 EUR-82.4%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)96.20 GBP-71.7%

No liability assumed, Date: 31.08.2016


All Events